A Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042

Launched by AHN-GOOK PHARMACEUTICALS CO.,LTD · Apr 2, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to study a new drug called AG2304 and how it behaves in the body, which is known as pharmacokinetics. Essentially, researchers want to understand how the drug is absorbed and processed in healthy adults. The trial is currently not recruiting participants, but when it begins, it will focus on healthy adults aged 19 to 65 who meet certain health criteria.

If you or someone you know is interested in participating, it's important to know that participants must not have taken any investigational drugs in the past six months. During the trial, participants will undergo various tests to ensure they are in good health before receiving AG2304. This study aims to provide vital information about the safety and effectiveness of the new drug, which could lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A healthy adults aged 19-65 years at the time of screening
• • Subjects who are deemed eligible based on the screening tests
• Exclusion Criteria:
• • Subjects who have taken the investigational drug within 6 months prior to the first dose
• • Other exclusions have been applied